14 November 2014

Bristol-Myers Squibb plans new biologics facility in Ireland

New York - 14 November 2014 - Bristol-Myers Squibb, a global biopharmaceutical company, plans to construct a new, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Approximately 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the facility when construction is completed, and the construction program is expected to create about 1,000 jobs. The company worked with Ireland's Department of Jobs, Enterprise and Innovation through IDA Ireland as part of the planned expansion.

The 30,000-square meter project will house six 15,000-liter bioreactors and a purification area as well as office and laboratory space. The plant will be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant. The completion of the facility, including commissioning and validation, is anticipated to take approximately four years and is estimated to be operational in 2019.

“Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in Bristol-Myers Squibb’s future,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. 

“I had the opportunity to meet with Bristol-Myers Squibb, and I'm delighted they chose Ireland as the location for this large, state-of-the-art facility. Not only will 1,000 construction jobs be created in the initial phase, but the facility will support up to 400 jobs for skilled professionals. The government has a plan to secure recovery so that Ireland can attract new jobs and investments such as those being announced today,” said Mr. Enda Kenny T.D., Prime Minister of Ireland.

Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project. The full cost of the facility, expected to be finalized in the second half of 2015, is anticipated to be comparable to the approximately $900 million investment to construct and operationalize the company’s biologics manufacturing facility in Devens, Massachusetts.